Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06626321
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-10-01
Brief Title:
Behavioral Economics to Improve Flu Vaccination Using EHR Nudges Replication
Sponsor:
None
Organization:
None
Study Overview
Official Title:
BE IMMUNE Behavioral Economics to IMprove and Motivate Vaccination Using Nudges Through the EHR A Replication Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BE IMMUNE Rep
Brief Summary:
This study will be a 6-month cluster randomized pragmatic replication trial to evaluate the effectiveness of personalized nudges to clinicians and patients relative to a control to increase flu vaccination rates among older adults in accordance with CDC guidelines This will include clinician and patient level nudge interventions with additional intensified nudge interventions for patients identified as high risk for not receiving a flu vaccine Among the intervention clinics patients will receive pre-visit text message reminders about the flu vaccine and clinicians will receive a default pended order in the visit encounter in the EHR along with monthly peer comparison feedback about their flu vaccine completion rate Patients identified as high risk for noncompletion will be individually randomized to receive an additional bidirectional text message nudge or the standard text messaging
Detailed Description:
Many older adults are at risk of illness hospitalization and death from vaccine-preventable diseases More than half of older adults in the United States are not vaccinated for flu which has remained relatively constant over the past decade and there are racial ethnic and socioeconomic disparities in care In this study we will evaluate personalized nudges to clinicians and patients to help increase flu vaccination rates during primary care visits among older adults at three distinct health systems with a particular focus on population subgroups at high risk for vaccine noncompletion In a partnership between Penn Medicine and University of Washington UW Medicine a 6-month multisite cluster randomized pragmatic trial with an additional intensification arm for high-risk patients was conducted from September 2023-February 2024 We will now conduct a 6-month replication trial at Lancaster General Health for the 2024-2025 flu season
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None